BioTuesdays

Tag - SVB Securities

Pliant Therapeutics
Markets

SVB starts Pliant Therapeutics at OW: PT $33

SVB Securities initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “outperform” rating and price target of $33. The stock closed at $19.22 on July 19. Pliant is a clinical-stage biopharmaceutical company...

July 20, 2022
Markets

SVB Securities starts Morphic Holding at OW; PT $45

SVB Securities launched coverage of Morphic Holding (NASDAQ:MORF) with an “outperform” rating and $45 price target. The stock closed at $24.99 on July 19. Morphic is a clinical-stage biotechnology company developing...

July 20, 2022
Selecta Biosciences
Markets

SVB starts Selecta Biosciences at OP; PT $7

SVB Securities initiated coverage of Selecta Biosciences (NASDAQ:SELB) with an “outperform” rating and $7 price target. The stock closed at 88 cents on June 3. Selecta is a clinical-stage biotech company advancing its...

June 6, 2022
PepGen
Markets

SVB Securities starts PepGen at OP; PT $40

SVB Securities launched coverage of PepGen (NASDAQ:PEPG) with an “outperform” rating and $40 price target. The stock closed at $10.88 on May 27. PepGen is a clinical-stage biotech advancing its enhanced delivery...

May 31, 2022
Markets

SVB cuts Avadel Pharma PT to $6 from $18

SVB Securities slashed the price target of Avadel Pharmaceuticals (NASDAQ:AVDL) to $6 from $18, but maintained an “overweight” rating, after the FDA delayed full approval of FT-218 because of a patent issue.  Shares of...

May 27, 2022
HilleVax
Markets

Analysts start HilleVax at buy, outperform

Analysts for Stifel and SVB Securities initiated coverage of HilleVax (NASDAQ:HLVX) with “buy” and “outperform” ratings, and price targets of $34 and $30, respectively. The stock closed at $9.50 on May 23. The company’s...

May 24, 2022
Amarin
Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022
Aligos-Therapeutics
Markets

SVB cuts Aligos to market perform; PT to $3 from $7

SVB Securities downgraded Aligos Therapeutics (NASDAQ:ALGS) to “market perform” from “outperform” and slashed its price target to $3, which is close to cash, from $7, citing a slow catalyst path ahead with a legal...

May 5, 2022
Opthea-Logo
Markets

SVB starts Opthea at OP; PT $25

SVB Securities launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $25 price target. The stock closed at $5.71 on April 25. Opthea is a clinical-stage biotechnology company focused on developing...

April 26, 2022